After hours on January 27, Shenzhen Stock Exchange issued a letter of concern to Jiangsu Akcome Science And Technology Co.Ltd(002610) , asking it to explain the specific basis for the setting of equity incentive performance evaluation indicators and whether they are realizable.
On January 26, Jiangsu Akcome Science And Technology Co.Ltd(002610) issued the equity incentive plan, which plans to grant a total of 18642600 shares to incentive objects. It is noteworthy that the performance evaluation index of Jiangsu Akcome Science And Technology Co.Ltd(002610) from 2022 to 2025 is a 10 fold increase in revenue. According to the performance forecast, Jiangsu Akcome Science And Technology Co.Ltd(002610) in 2021, the net profit loss is 195 million yuan – 390 million yuan.
The market showed that as of the closing on January 27, Jiangsu Akcome Science And Technology Co.Ltd(002610) closed at 3.72 yuan / share, up 3.33%.
Shenzhen Stock Exchange issued a concern letter
The attention letter pointed out that the growth rate of performance evaluation indicators in Jiangsu Akcome Science And Technology Co.Ltd(002610) this incentive plan is high. The company is required to supplement the specific basis for setting performance evaluation indicators and whether they are realizable in combination with the development trend of its industry and main business, the growth rate of operating revenue in recent three years, orders on hand, etc. The company added the specific reasons for setting only a single assessment index of operating income at the performance level of the company in this incentive plan, and whether it complies with the relevant provisions of Article 11 of the measures for the administration of equity incentives of listed companies.
Jiangsu Akcome Science And Technology Co.Ltd(002610) according to the previously released draft of 2022 stock option and restricted stock incentive plan, this incentive plan includes two parts: stock option incentive plan and restricted stock incentive plan. It is proposed to grant a total of 18642600 shares to incentive objects, and the subject stock category involved is A-share common stock, accounting for about 0.416% of the company’s total share capital of 4.48 billion shares, Among them, 14914100 equity shares were granted for the first time.
The total number of incentive objects granted for the first time is 120, including directors, senior managers, core managers, core technicians and core business personnel who served in the company (including subsidiaries) when the company announced the incentive plan. The exercise price of stock options is 4.33 yuan / share, and the grant price of restricted shares is 2.16 yuan / share. The granted stock options and restricted shares shall become effective and the restrictions on sale shall be lifted in four phases after 12 months from the date of completion of the grant.
Jiangsu Akcome Science And Technology Co.Ltd(002610) the performance evaluation target of this equity incentive is set to take the operating revenue in 2021 as the base, the growth rate of operating revenue in 2022 is not less than 200%, the growth rate of operating revenue in 2023 is not less than 400%, the growth rate of operating revenue in 2024 is not less than 600%, and the growth rate of operating revenue in 2025 is not less than 1000%.
This means that the operating revenue target of Jiangsu Akcome Science And Technology Co.Ltd(002610) will increase tenfold in four years. So what is the company’s current performance?
the maximum advance loss in 2021 is 390 million yuan
According to public information, Jiangsu Akcome Science And Technology Co.Ltd(002610) is a high-tech enterprise focusing on two core businesses: new energy manufacturing and new energy services. The company was founded in March 2006 and landed on the small and medium-sized board of Shenzhen Stock Exchange in August 2011.
On the evening of January 25, Jiangsu Akcome Science And Technology Co.Ltd(002610) disclosed the performance forecast. It is estimated that the annual operating revenue in 2021 will be 2.5-3 billion yuan, compared with 3.016 billion yuan in the same period of last year; The net profit attributable to the parent company was a loss of 195 million yuan to 390 million yuan, and the profit in the same period of last year was 22.0797 million yuan.
Jiangsu Akcome Science And Technology Co.Ltd(002610) said that the decline of the company’s performance during the reporting period was mainly due to the impact of the foreign covid-19 epidemic, the company’s overseas business market development was limited, the company’s export sales of manufacturing products accounted for a large proportion, and the manufacturing operating revenue and operating performance decreased compared with the same period of the previous year; The prices of main raw materials such as aluminum, steel, silicon wafer and battery chip have increased significantly, and the sea freight has increased significantly, resulting in a decline in the gross profit of the company’s manufacturing products; The company’s new high-efficiency battery project is in the production capacity climbing stage. The project investment, construction, operation and personnel reserve all need the company’s continuous capital investment, which affects the company’s profits and losses.
Zhongtai Securities Co.Ltd(600918) said that the epidemic affected short-term performance and was optimistic about the company’s heterojunction layout for a long time. Relying on the continuous accumulation in the industry over the years, the company has obvious competitive advantages in the scale, technology and cost of heterojunction batteries and components.
